The recent Nobel Prize recognition of AI’s ability to model molecular interactions signals the high expectations for improving drug discovery. However, leading companies are already applying AI tools to improve their productivity for developing existing assets via improved biomarker selection and pharmacokinetics modeling. This panel will feature lessons learned from leaders in this space that other companies can consider applying themselves.​